Please login to the form below

Not currently logged in
Email:
Password:

BMS and Pfizer's Eliquis in trial success

Bristol-Myers Squibb and Pfizer have revealed successful topline results of the phase III ARISTOTLE trial of Eliquis (apixaban) for atrial fibrillation 

Bristol-Myers Squibb (BMS) and Pfizer have revealed successful topline results of the phase III ARISTOTLE trial of Eliquis (apixaban) for atrial fibrillation. 

In this study of patients with atrial fibrillation and at least one additional risk factor for stroke, Eliquis met the primary efficacy objective of non-inferiority to warfarin on the combined outcome of stroke (ischemic, hemorrhagic or unspecified type) and systemic embolism. 

The drug met the key secondary endpoints of superiority on efficacy and on International Society on Thrombosis and Hemostasis major bleeding compared to warfarin.

Eliquis, a new oral direct Factor Xa inhibitor, is being developed by the alliance of BMS and Pfizer.

The companies expect to submit regulatory filings in atrial fibrillation in the US and Europe in the third or fourth quarter of 2011.

The detailed results of the ARISTOTLE study will be presented on August 28 at the European Society of Cardiology Congress 2011 in Paris.

23rd June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...